HIF稳定剂Desidustat保护免受补充介导的疾病
Vishal J Patel1, Amit A Joharapurkar1, Samadhan G Kshirsagar1
1Department of Pharmacology and Toxicology, Zydus Research Centre, Zydus Lifesciences Limited, Moraiya, Ahmedabad, India.
Drug research
|July 11, 2024
概括
低氧诱导因子 (HIF) 稳定剂Desidustat通过抑制替代补充系统来减少补充介导疾病中的和视网膜损伤. 这项研究突出了欲望的地位.
科学领域:
- 免疫学 免疫学 免疫学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 眼科医生 眼科 眼科
背景情况:
- 补体级联对宿主防御至关重要,但其失调,特别是替代途径,导致炎症性脏和视网膜疾病.
- 炎症诱导的组织缺氧激活了缺氧诱导因子 (HIF),这是细胞适应的关键调节者.
- 在补充介导病理中准HIF的治疗潜力在很大程度上仍未被探索.
研究的目的:
- 在补充介导性脏和视网膜疾病的临床前模型中研究HIF稳定剂deshiustat的疗效.
- 阐明脱酸盐影响补充激活和相关病理学的机制.
主要方法:
- 德西杜沙特 (15毫克/公斤) 已被口服给接受损伤模型 (LPS,多克索鲁比辛,BSA过载) 和视网膜退化模型的小鼠.
- 评估了补充激活标志物 (MAC形成,B因子活性,C3沉积) 和疾病特异性参数 (蛋白尿症,氧化应激标志物,炎症性细胞因子).
- 评估了脱希斯塔特对不同补充通路 (替代性,莱克,古典) 的影响.
主要成果:
- 在多个模型中,desidustat显著改善了损伤,并减少了视网膜退化.
- 用脱苏他治疗降低了补体激活,包括膜攻击复合体 (MAC) 形成和B因子活性.
- 在膜性脏病中,脱沙特降低了C3沉积,蛋白尿,甲酸和IL-1β,同时增加了超氧化物脱酶,特别是通过通过B因子抑制替代补充途径来抑制替代补充途径.
结论:
- 德西杜沙特在补充介导的脏和视网膜疾病中有效地减轻组织损伤.
- 脱希斯塔特的治疗效益归因于其对替代补充路径的特定抑制,由B因子介导.
- 用脱沙他特稳定HIF是一种有前途的治疗策略,用于管理补充介导的炎症性疾病.
相关概念视频
Humoral Immune Responses
72.5K
Overview
72.5K
Immunodeficiency Diseases
933
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
933
Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
267
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
267
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
628
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
628
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K


